ADMA Biologics, Inc.
ADMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3,997 | $1,012 | $768 | $197 |
| - Cash | $103 | $51 | $87 | $51 |
| + Debt | $82 | $141 | $154 | $103 |
| Enterprise Value | $3,976 | $1,102 | $836 | $249 |
| Revenue | $426 | $258 | $154 | $81 |
| % Growth | 65.2% | 67.6% | 90.4% | – |
| Gross Profit | $220 | $89 | $35 | $1 |
| % Margin | 51.5% | 34.4% | 22.9% | 1.4% |
| EBITDA | $148 | $5 | -$40 | -$53 |
| % Margin | 34.6% | 2% | -25.6% | -65.6% |
| Net Income | $198 | -$28 | -$66 | -$72 |
| % Margin | 46.4% | -10.9% | -42.8% | -88.5% |
| EPS Diluted | 0.81 | -0.13 | -0.43 | -0.61 |
| % Growth | 723.1% | 69.8% | 29.5% | – |
| Operating Cash Flow | $119 | $9 | -$60 | -$112 |
| Capital Expenditures | -$9 | -$5 | -$14 | -$14 |
| Free Cash Flow | $110 | $4 | -$73 | -$126 |